Increased PHOSPHO1 and alkaline phosphatase expression during the anabolic bone response to intermittent parathyroid hormone delivery
暂无分享,去创建一个
A. Pitsillides | J. Millán | C. Farquharson | V. Macrae | K. Staines | L. Stephen | M. Hopkinson | S. N. Jayash | K. Myers | Kirsty Little | D. Houston
[1] A. Koh,et al. Anabolic actions of parathyroid hormone in a hypophosphatasia mouse model , 2022, Osteoporosis International.
[2] A. Pitsillides,et al. Increased PHOSPHO1 expression mediates cortical bone mineral density in renal osteodystrophy , 2021, bioRxiv.
[3] C. Schalin-Jäntti,et al. Physiology of Calcium Homeostasis: An Overview. , 2021, Endocrinology and metabolism clinics of North America.
[4] C. Farquharson,et al. Endocrinology of Bone and Growth Disorders , 2021, Reference Module in Biomedical Sciences.
[5] L. Mccauley,et al. Anabolic actions of PTH in murine models: two decades of insights , 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] L. Bonewald,et al. Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23 , 2020, Calcified Tissue International.
[7] J. Millán,et al. How To Build a Bone: PHOSPHO1, Biomineralization, and Beyond , 2019, JBMR plus.
[8] A. Boyde,et al. A distinctive patchy osteomalacia characterises Phospho1‐deficient mice , 2017, Journal of anatomy.
[9] C. Farquharson,et al. The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures , 2016, Calcified Tissue International.
[10] H. Yasuda,et al. Smpd3 Expression in both Chondrocytes and Osteoblasts Is Required for Normal Endochondral Bone Development , 2016, Molecular and Cellular Biology.
[11] R. Pacifici. T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone , 2016, Annals of the New York Academy of Sciences.
[12] J. Millán,et al. Phospho1 deficiency transiently modifies bone architecture yet produces consistent modification in osteocyte differentiation and vascular porosity with ageing , 2015, Bone.
[13] J. Millán,et al. Alkaline Phosphatase and Hypophosphatasia , 2015, Calcified Tissue International.
[14] M. Razzaque,et al. Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity. , 2015, BoneKEy reports.
[15] J. Bilezikian,et al. Parathyroid hormone: anabolic and catabolic actions on the skeleton. , 2015, Current opinion in pharmacology.
[16] A. Boyde,et al. An Investigation of the Mineral in Ductile and Brittle Cortical Mouse Bone , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] L. Bonewald,et al. The parathyroid hormone-regulated transcriptome in osteocytes: parallel actions with 1,25-dihydroxyvitamin D3 to oppose gene expression changes during differentiation and to promote mature cell function. , 2015, Bone.
[18] J. Millán,et al. Dual Role of the Trps1 Transcription Factor in Dentin Mineralization* , 2014, The Journal of Biological Chemistry.
[19] C. Farquharson,et al. Direct stimulation of bone mass by increased GH signalling in the osteoblasts of Socs2−/− mice , 2014, The Journal of endocrinology.
[20] J. Millán. The Role of Phosphatases in the Initiation of Skeletal Mineralization , 2013, Calcified Tissue International.
[21] M. Selig,et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] H. Kiyonari,et al. Osterix Regulates Calcification and Degradation of Chondrogenic Matrices through Matrix Metalloproteinase 13 (MMP13) Expression in Association with Transcription Factor Runx2 during Endochondral Ossification* , 2012, The Journal of Biological Chemistry.
[23] A. Pitsillides,et al. Extracellular Matrix Mineralization Promotes E11/gp38 Glycoprotein Expression and Drives Osteocytic Differentiation , 2012, PloS one.
[24] N. Jørgensen,et al. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans , 2012, Scandinavian journal of clinical and laboratory investigation.
[25] Y. Hannun,et al. A cell-autonomous requirement for neutral sphingomyelinase 2 in bone mineralization , 2011, The Journal of cell biology.
[26] B. Langdahl,et al. Medical Treatment of Osteoporotic Vertebral Fractures , 2011, Therapeutic advances in musculoskeletal disease.
[27] M. McKee,et al. Loss of Skeletal Mineralization by the Simultaneous Ablation of PHOSPHO1 and Alkaline Phosphatase Function: A Unified Model of the Mechanisms of Initiation of Skeletal Calcification , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] Simon R. Goodyear,et al. PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fractures. , 2010, Bone.
[29] M. Karsdal,et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. , 2010, Bone.
[30] G. Loots,et al. Parathyroid Hormone (PTH)–Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] H. Ryoo,et al. Upregulation of smpd3 via BMP2 stimulation and Runx2. , 2009, BMB reports.
[32] N. Sims,et al. EphrinB2 Regulation by PTH and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] R. Shivdasani,et al. Uncoupling of chondrocyte differentiation and perichondrial mineralization underlies the skeletal dysplasia in tricho-rhino-phalangeal syndrome. , 2008, Human molecular genetics.
[34] A. Parfitt,et al. Perspective: Quantifying Osteoblast and Osteocyte Apoptosis: Challenges and Rewards , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] J. Parsons,et al. Preliminary trial of low doses of human parathyroid hormone 1–34 peptide in treatment of osteoporosis , 1975, Calcified Tissue Research.
[36] M. Kneissel,et al. SOST is a target gene for PTH in bone. , 2005, Bone.
[37] L. Gelbert,et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray , 2005, Journal of cellular biochemistry.
[38] P. Sadler,et al. Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities. , 2004, The Biochemical journal.
[39] H. Anderson,et al. Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. , 2004, The American journal of pathology.
[40] L. Qin,et al. Parathyroid hormone: a double-edged sword for bone metabolism , 2004, Trends in Endocrinology & Metabolism.
[41] B. L. Riggs,et al. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone , 2003, Journal of cellular biochemistry.
[42] E. Eriksen. Primary hyperparathyroidism: lessons from bone histomorphometry. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[43] M. Rubin,et al. The potential of parathyroid hormone as a therapy for osteoporosis. , 2002, International journal of fertility and women's medicine.
[44] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[45] R. L. Cain,et al. Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation. , 2001, Endocrinology.
[46] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[47] R. L. Cain,et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. , 2001, Endocrinology.
[48] R. Recker,et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. , 1999, The Journal of clinical endocrinology and metabolism.
[49] A. Yamaguchi,et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. , 1997, The Journal of clinical investigation.
[50] J. Millán,et al. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia , 1997, Developmental dynamics : an official publication of the American Association of Anatomists.
[51] R. Terkeltaub,et al. Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1. Relevance to calcium pyrophosphate dihydrate deposition disea , 1994, Arthritis and rheumatism.
[52] E. Canalis,et al. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. , 1989, The Journal of clinical investigation.
[53] J. Heersche,et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. , 1982, Endocrinology.